The British shoe provider Dr. Martens PLC confirmed his forecasts for the current financial year 2025/26 on Thursday. Since the beginning of the fiscal year on April 1, sales development had been “in the context of expectations”, the company said in the run -up to its annual general meeting in London. The goals for the year as a whole at the beginning of June therefore remained “unchanged”.
The British home market suffers from difficult framework conditions
In the past few months, its own retail in America has “continued to be positive”, said Dr. Martens with without publishing concrete figures. The decisive factor for this was in particular the shops with non -price -reduced products in their own stores.
In the individual markets in the individual markets, on the other hand, in the individual markets, on the other hand, in the EMEA region, which includes Europe, the Middle East and Africa. The business in the UK in particular were still characterized by a “challenging” market environment.
According to the shoe provider, the shoe provider again achieved “good growth” in the Asian-Pacific room (APAC). The company expressly emphasized the “particularly strong results” in South Korea.
Dr. Martens relies on the effects of the ongoing reform program
With a view to the upcoming autumn winter season, Dr. Martens a “healthy” order situation. In EMEA, the present number of order had exceeded the level of the previous year, and in America they were essentially stable, the company said.
The shoe provider emphasized that he would continue to concentrate on the implementation of his “Levers for Growth” strategy presented at the beginning of June. The focus of the plans is therefore “more consumers: to address more, create more purchase events, to make sales in line with the market and to simplify the operating model”.
The company wants to present more specific information about the further progress of reforms and their first effects in November when it publishes its complete results for the first half of the year.